Coincidental Onset of Ocular Myasthenia Gravis Following ChAdOx1 n-CoV-19 Vaccine against Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2).
Giuliana Galassi, Vittorio Rispoli, Erika Iori, Alessandra Ariatti, Alessandro Marchioni
Abstract
BACKGROUND: The Oxford-AstraZeneca vaccine ChAdOx1 (AZD1222, Vaxzevria) is playing a crucial role in counteracting the coronavirus disease-2019 (COVID-19) pandemic [1]. Since March 2021, reports of unexpected thrombotic events associated with thrombocytopenia and vaccination have been published [2]. To the best of our knowledge there is only one report about vaccination-associated myasthenia gravis (MG) occurring after a second dose of BNT162b2 (Pfizer-BioNTech).
Topics & Concepts
Myasthenia gravisMedicineVaccinationPandemicCoronavirus disease 2019 (COVID-19)CoronavirusSevere acute respiratory syndrome coronavirus 2 (SARS-CoV-2)2019-20 coronavirus outbreakVirologyImmunologyPediatricsDiseaseInternal medicineInfectious disease (medical specialty)OutbreakHeparin-Induced Thrombocytopenia and ThrombosisPeripheral Neuropathies and DisordersVasculitis and related conditions